References |
Xu et al 2020; Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). Markus H. Moehler, Ken Kato, Hendrik-Tobias Arkenau, Do-Youn Oh, Josep Tabernero, Marcia Cruz-Correa, HongWei Wang, Hui Xu, Jiang Li, Silu Yang, and Rui-hua Xu; Journal of Clinical Oncology 2023 41:4_suppl, 286-286 |